ClinicalTrials.gg
TerminatedNCT05055258KVD824-201Updated May 6, 2026Results posted

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

A Phase 2 interventional study of KVD824 and Placebo to KVD824 in Angioedema, Hereditary, Types I and II, sponsored by KalVista Pharmaceuticals, Ltd.. Terminated at 33 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Phase 2, Interventional, and Prevention

How we know

Why this study was terminated
Terminated by Sponsor due to adverse events reported

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

02

Conditions studied

  • Angioedema, Hereditary, Types I and II

Keywords

  • KVD824
  • KOMPLETE
03

In context

Lead sponsor

KalVista Pharmaceuticals, Ltd. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.

First submitted before KalVista Pharmaceuticals, Ltd. became part of Chiesi Farmaceutici S.p.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 18 years of age and older.
  2. Confirmed diagnosis of HAE type I or II at any time in the medical history:

    1. Documented clinical history consistent with HAE (subcutaneous or mucosal, nonpruritic swelling episodes without accompanying urticaria) AND EITHER
    2. Diagnostic testing results obtained prior to randomization that confirm HAE Type I or II: C1-INH functional level \<40% of the normal level. Subjects with functional C1-INH level 40-50% of the normal level may be enrolled if they also have a C4 level below the normal range. Testing may be obtained from central or local laboratories or obtained from documented historical testing results. Subjects may be restested at anytime prior to randomization if results are incongruent with clinical history or believed by the Investigator to be confounded by recent prophylactic or therapeutic C1 INH use, OR
    3. Documented genetic results that confirm known mutations for HAE Type I or II.
  3. Subject has access to and ability to use conventional treatment for HAE attacks.
  4. Subject is willing to cease any current medications being taken for HAE prophylaxis and Investigator determines that doing so would not place the subject at any undue safety risk.
  5. Subject's last dose of attenuated androgens was at least 28 days prior to first dose of IMP.
  6. During the Run-in Period subject meets one of the following criteria:

    1. Two Investigator-confirmed attacks in the first 4-week period.
    2. Three Investigator-confirmed attacks in ≤8 weeks.
  7. Subjects who are fertile and heterosexually active must adhere to requirements throughout the trial as follows:

    a) Female subjects must agree to use at least one highly effective contraception method from the Screening Visit until the end of the trial. Highly effective methods of contraception include: i) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral/injectable/implantable (hormonal contraception that contains estrogen including ethinylestradiol is excluded per Exclusion 4).

    ii) Intrauterine device (IUD). iii) Intrauterine hormone-releasing system (IUS). iv) Bilateral tubal occlusion. v) Vasectomized partner (provided that the partner is the sole sexual partner of the female subject of and that the vasectomized partner has received medical assessment of surgical success).

    b) Male subjects with a female partner of childbearing potential must agree to use condoms for the entire Treatment Period AND for 90 days following the final dose of medicinal product (IMP). Female partners are encouraged to use contraception as outlined in Inclusion 7a) from the Screening Visit until the end of the trial. Hormonal contraception that contains estrogen including ethinylestradiol is acceptable for the female partner.

  8. Subjects who are not fertile or not sexually active, as defined below, do not require contraception.

    1. Subjects who refrain from heterosexual intercourse during the trial if the reliability of the heterosexual abstinence has been evaluated in relation to the duration of the clinical trial and is the preferred and usual lifestyle of the subject.
    2. Male subjects who are surgically sterile (e.g. vasectomized with medical assessment of surgical success).
    3. Female subjects who are surgically sterile (e.g. status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post menopausal for at least 12 months.
  9. Subjects must be able to swallow trial tablets whole.
  10. Subjects assessed by the Investigator must be able to appropriately receive and store IMP, and be able to read, understand, and complete the eDiary.
  11. Investigator believes that the subject is willing and able to adhere to all protocol requirements.
  12. Subject provides signed and is willing and capable of complying with trial requirements and procedures.

Exclusion criteria

Exclusion Criteria

  1. Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
  2. A history of poor response to C1-INH therapy or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
  3. Use of angiotensin converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
  4. Any estrogen containing medications with systemic absorption (such as oral including ethinylestradiol or hormonal replacement therapy) after the Screening Visit or within 7 days prior to randomization.
  5. Use of narrow therapeutic index drugs metabolized by or CYP2C9 or transported by OAT1, OCT2, and OATP1B1, starting at screening, as determined by the Investigator.
  6. Use of strong CYP3A4 inhibitors and inducers during participation in the trial, starting at the Screening Visit.

    Note: These medications include but are not limited to the following:

    Inhibitors: boceprevir, clarithromycin, cobicistat, dasabuvir, denoprevir, elvitegravir, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, tipranavir, troleandomycin, and voriconazole.

    Inducers: apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort.

  7. Inadequate organ function, including but not limited to;

    1. (ALT) > 2x (ULN).
    2. Aspartate aminotransferase (AST) > 2x ULN.
    3. direct > 1.25x ULN.
    4. (INR) > 1.2.
    5. Clinically significant hepatic impairment defined as a B or C.
    6. Estimated (eGFR) \<60 mL/min.
  8. Any clinically significant comorbidity or systemic dysfunction that in the opinion of the Investigator would jeopardize the safety of the subject by participating in the trial.
  9. History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
  10. Known to KVD824 or placebo or to any of the .
  11. Any prior use of any gene therapy treatment for HAE.
  12. Participation in any interventional clinical trial, including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of investigational drug prior to screening.
  13. Any pregnant or breastfeeding subject.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    300 mg KVD824

    300 mg KVD824 twice a day for 12 weeks

    Drug: KVD824

  • Experimental
    600 mg KVD824

    Two 300 mg KVD824 tablets twice a day for 12 weeks

    Drug: KVD824

  • Experimental
    900 mg KVD824

    Three 300 mg KVD824 tablets twice a day for 12 weeks

    Drug: KVD824

  • Placebo comparator
    Placebo to KVD824

    One, two or three placebo tablets to be taken twice a day for 12 weeks

    Drug: Placebo to KVD824

Interventions

06

What researchers measure

Primary outcomes

  1. The Rate of Investigator-confirmed HAE Attacks During the Treatment Period

    To examine the number of investigator-confirmed attacks whilst on treatment compared to placebo. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of Subjects Without Investigator-confirmed HAE Attacks During the Treatment Period.

    Logistic regression on subjects were measured without investigator-confirmed HAE Attacks (FAS). Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

    Time frame: 12 weeks

  2. Rate of Investigator-confirmed HAE Attacks That Require Conventional Treatment During the Treatment Period.

    A summary of negative binomial regression on investigator-confirmed HAE attacks with conventional treatment is presented for the FAS. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

    Time frame: 12 weeks

  3. Angioedema Quality of Life Questionnaire (AE-QoL) Total Score During the Treatment Period (Change From Baseline)

    AE-QoL is a quality of life questionnaire with a range of 0 (minimum) to 100 (maximum). A total score of 100 indicates worst possible impairment. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

    Time frame: 12 weeks

  4. Angioedema Control Test (AECT) Score During the Treatment Period (Change From Baseline).

    AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

    Time frame: 12 weeks

  5. Proportion of Subjects With an AECT Score ≥12 at the End of the Treatment Period.

    AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

    Time frame: 12 weeks

07

Results

Posted May 6, 2026

Participant flow

Recruitment Start Date - 06Aug21-27Oct22 First Patient Enrolled - 18Nov21 Long term follow-up planned: No Independent data monitoring committee (IDMC) involvement: No

Participant flow — Overall Study
Milestone300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
Started7877
Completed5442
Not completed2435
Withdrew: Trial termination by sponsor2212
Withdrew: Adverse event0221
Withdrew: Withdrawal by subject0002

Outcome measures

PrimaryThe Rate of Investigator-confirmed HAE Attacks During the Treatment Period

To examine the number of investigator-confirmed attacks whilst on treatment compared to placebo. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

Time frame:
12 weeks
Reported as:
Mean · HAE attacks
The Rate of Investigator-confirmed HAE Attacks During the Treatment Period
HAE attacks300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
The Rate of Investigator-confirmed HAE Attacks During the Treatment Period1.476 (0.786 to 2.774)1.072 (0.534 to 2.152)1.566 (0.814 to 3.012)2.380 (1.282 to 4.418)
Statistical analysis
  • 300 mg KVD824 BID vs Placebo to KVD824 BID · Negative binomial regression model · p = 0.2862 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Hae rate ratio (active vs. placebo): 0.62 · 95% CI 0.258 to 1.492These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 600 mg KVD824 BID vs Placebo to KVD824 BID · Negative binomial regression model · p = 0.0918 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Hae rate ratio (active vs. placebo): 0.45 · 95% CI 0.178 to 1.138These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 900 mg KVD824 BID vs Placebo to KVD824 BID · Negative binomial regression model · p = 0.3685 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Hae rate ratio (active vs. placebo): 0.658 · 95% CI 0.264 to 1.639These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
SecondaryProportion of Subjects Without Investigator-confirmed HAE Attacks During the Treatment Period.

Logistic regression on subjects were measured without investigator-confirmed HAE Attacks (FAS). Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Without Investigator-confirmed HAE Attacks During the Treatment Period.
Participants300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
Proportion of Subjects Without Investigator-confirmed HAE Attacks During the Treatment Period.1231
Statistical analysis
  • 300 mg KVD824 BID vs Placebo to KVD824 BID · Regression, Logistic · p = 0.9798 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Odds ratio (or): 1.04 · 95% CI 0.07 to 15.6These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 600 mg KVD824 BID vs Placebo to KVD824 BID · Regression, Logistic · p = 0.8112 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Odds ratio (or): 1.36 · 95% CI 0.11 to 17.2These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 900 mg KVD824 BID vs Placebo to KVD824 BID · Regression, Logistic · p = 0.3683 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Odds ratio (or): 3.09 · 95% CI 0.26 to 36.1These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
SecondaryRate of Investigator-confirmed HAE Attacks That Require Conventional Treatment During the Treatment Period.

A summary of negative binomial regression on investigator-confirmed HAE attacks with conventional treatment is presented for the FAS. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

Time frame:
12 weeks
Reported as:
Least squares mean · Est. treated attack rate over 4 weeks
Rate of Investigator-confirmed HAE Attacks That Require Conventional Treatment During the Treatment Period.
Est. treated attack rate over 4 weeks300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
Rate of Investigator-confirmed HAE Attacks That Require Conventional Treatment During the Treatment Period.1.003 (0.461 to 2.183)1.093 (0.485 to 2.464)1.229 (0.554 to 2.728)1.635 (0.754 to 3.548)
Statistical analysis
  • 300 mg KVD824 BID vs Placebo to KVD824 BID · Negative binomial regression model · p = 0.3833 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Hae rate ratio (active vs. placebo): 0.613 · 95% CI 0.204 to 1.84These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 600 mg KVD824 BID vs Placebo to KVD824 BID · Negative binomial regression model · p = 0.4819 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Hae rate ratio (active vs. placebo): 0.668 · 95% CI 0.217 to 2.055These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 900 mg KVD824 BID vs Placebo to KVD824 BID · Negative binomial regression model · p = 0.6147 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Hae rate ratio (active vs. placebo): 0.752 · 95% CI 0.248 to 2.282These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
SecondaryAngioedema Quality of Life Questionnaire (AE-QoL) Total Score During the Treatment Period (Change From Baseline)

AE-QoL is a quality of life questionnaire with a range of 0 (minimum) to 100 (maximum). A total score of 100 indicates worst possible impairment. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

Time frame:
12 weeks
Reported as:
Mean · Scores on a Scale 0-100
Angioedema Quality of Life Questionnaire (AE-QoL) Total Score During the Treatment Period (Change From Baseline)
Scores on a Scale 0-100300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
Angioedema Quality of Life Questionnaire (AE-QoL) Total Score During the Treatment Period (Change From Baseline)-5.46 ± 16.281-15.69 ± 23.097-3.68 ± 16.8890.74 ± 16.398
Statistical analysis
  • 300 mg KVD824 BID vs Placebo to KVD824 BID · ANCOVA · p = 0.7676 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Ls means difference from placebo: 3.11 · 95% CI -18.74 to 24.96These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 600 mg KVD824 BID vs Placebo to KVD824 BID · ANCOVA · p = 0.4367 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Ls means difference from placebo: -8.38 · 95% CI -30.59 to 13.82These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 900 mg KVD824 BID vs Placebo to KVD824 BID · ANCOVA · p = 0.73 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Ls means difference from placebo: 3.67 · 95% CI -18.42 to 25.77These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
SecondaryAngioedema Control Test (AECT) Score During the Treatment Period (Change From Baseline).

AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

Time frame:
12 weeks
Reported as:
Mean · Scores on a Scale 0-16
Angioedema Control Test (AECT) Score During the Treatment Period (Change From Baseline).
Scores on a Scale 0-16300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
Angioedema Control Test (AECT) Score During the Treatment Period (Change From Baseline).2.6 ± 4.935.5 ± 3.831.3 ± 6.68-1.5 ± 3.70
Statistical analysis
  • 300 mg KVD824 BID vs Placebo to KVD824 BID · ANCOVA · p = 0.6224 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Ls means difference from placebo: 1.48 · 95% CI -4.73 to 7.69These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 600 mg KVD824 BID vs Placebo to KVD824 BID · ANCOVA · p = 0.2506 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Ls means difference from placebo: 3.7 · 95% CI -2.86 to 10.27These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 900 mg KVD824 BID vs Placebo to KVD824 BID · ANCOVA · p = 0.9969 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Ls means difference from placebo: 0.01 · 95% CI -6.44 to 6.47These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
SecondaryProportion of Subjects With an AECT Score ≥12 at the End of the Treatment Period.

AECT is a 4-item patient-reported outcome measure. The total score is from 0 (minimum) to 16 (maximum). A higher score indicates a higher level of angioedema control. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With an AECT Score ≥12 at the End of the Treatment Period.
Participants300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
YES4521
NO3143
MISSING0213
Statistical analysis
  • 300 mg KVD824 BID vs Placebo to KVD824 BID · Regression, Logistic · p = 0.3171 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Odds ratio (or): 4 · 95% CI 0.3 to 60.3These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 600 mg KVD824 BID vs Placebo to KVD824 BID · Regression, Logistic · p = 0.0891 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Odds ratio (or): 15 · 95% CI 0.7 to 339.4These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.
  • 900 mg KVD824 BID vs Placebo to KVD824 BID · Regression, Logistic · p = 0.7726 (These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.) · Odds ratio (or): 1.5 · 95% CI 0.1 to 26These results should be interpreted with caution acknowledging that an insufficient number of subjects were randomized and were on study for too short a period to achieve adequate power to detect treatment effects between KVD824 and placebo groups.

Adverse events

Collected over Safety analyses were performed by treatment group using the SAF and were presented during treatment. period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
300 mg KVD824 BID0/7 (0%)1/7 (14.3%)5/7 (71.4%)
600 mg KVD824 BID0/8 (0%)1/8 (12.5%)6/8 (75%)
900 mg KVD824 BID0/7 (0%)2/7 (28.6%)6/7 (85.7%)
Placebo to KVD824 BID0/7 (0%)0/7 (0%)1/7 (14.3%)
Most frequent serious events
Most frequent serious events
Event300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/70/81/70/7
Hepatic steatosisHepatobiliary disorders0/71/81/70/7
Hepatitis acuteHepatobiliary disorders0/70/81/70/7
Laryngeal oedemaRespiratory, thoracic and mediastinal disorders1/70/80/70/7
Most frequent other events
Showing 10 of 41
Most frequent other events
Event300 mg KVD824 BID600 mg KVD824 BID900 mg KVD824 BIDPlacebo to KVD824 BID
HeadacheNervous system disorders0/72/80/70/7
COVID-19Infections and infestations1/72/81/70/7
Hepatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/70/81/70/7
AstheniaGeneral disorders1/70/80/70/7
Menstruation irregularReproductive system and breast disorders0/70/81/70/7
CoughRespiratory, thoracic and mediastinal disorders1/70/80/70/7
Laryngeal oedemaRespiratory, thoracic and mediastinal disorders1/70/80/70/7
Mixed anxiety and depressive disorderPsychiatric disorders0/70/80/71/7
Alanine aminotransferase increasedInvestigations1/71/81/70/7
Aspartate aminotransferase increasedInvestigations0/70/81/70/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)300 mg KVD824600 mg KVD824900 mg KVD824Placebo to KVD824Total
<=18 years00000
Between 18 and 65 years586726
>=65 years20103
Age, Continuous
Age, Continuous(years)300 mg KVD824600 mg KVD824900 mg KVD824Placebo to KVD824Total
Median46.0 (25 to 74)44.0 (23 to 61)35.0 (25 to 66)53.0 (26 to 57)47.0 (23 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)300 mg KVD824600 mg KVD824900 mg KVD824Placebo to KVD824Total
Female643316
Male144413
Race (NIH/OMB)
Race (NIH/OMB)(Participants)300 mg KVD824600 mg KVD824900 mg KVD824Placebo to KVD824Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American11002
White667524
More than one race00011
Unknown or Not Reported01012
Region of Enrollment
Region of Enrollment(participants)300 mg KVD824600 mg KVD824900 mg KVD824Placebo to KVD824Total
Puerto Rico10001
Hungary11002
United States14128
Czechia01102
United Kingdom00112
North Macedonia10012
Italy11125
Australia10102
France01012
Bulgaria00101
Germany10102
08

Study locations

33 sites
  • KalVista Investigative Site
    Birmingham, Alabama 35294, United States
  • KalVista Investigative Site
    Scottsdale, Arizona 85251, United States
  • KalVista Investigative Site
    La Jolla, California 92093, United States
  • KalVista Investigative Site
    Santa Monica, California 90404, United States
  • KalVista Investigative Site
    Centennial, Colorado 80112, United States
  • KalVista Investigative Site
    Tampa, Florida 33620, United States
  • KalVista Investigative Site
    Chevy Chase, Maryland 20815, United States
  • KalVista Investigative Site
    Boston, Massachusetts 02114, United States
  • KalVista Investigative Site
    St Louis, Missouri 63110, United States
  • KalVista Investigative Site
    Cincinnati, Ohio 45231, United States
  • KalVista Investigative Site
    Hershey, Pennsylvania 17033, United States
  • KalVista Investigative Site
    Dallas, Texas 75390, United States
  • KalVista Investigative Site
    Spokane, Washington 99204, United States
  • KalVista Investigative Site
    Campbelltown, New South Wales, Australia
  • KalVista Investigative Site
    Sofia, Bulgaria
  • KalVista Investigative Site
    North York, Ontario, Canada
  • KalVista Investigative Site
    Brno, Czechia
  • KalVista Investigative Site
    Prague, Czechia
  • KalVista Investigative Site
    Grenoble, France
  • KalVista Investigative Site
    Paris, France
  • KalVista Investigative Site
    Mainz, Rhineland-Palatinate, Germany
  • KalVista Investigative Site
    Berlin, Germany
  • KalVista Investigative Site
    Frankfurt am Main, Germany
  • KalVista Investigative Site
    Budapest, Hungary
  • KalVista Investigative Site
    Milan, Italy
  • KalVista Investigative Site
    Padova, Italy
  • KalVista Investigative Site
    Grafton, Auckland, New Zealand
  • KalVista Investigative Site
    Skopje, North Macedonia
  • KalVista Investigative Site
    San Juan, Puerto Rico
  • KalVista Investigative Site
    Birmingham, United Kingdom
  • KalVista Investigative Site
    Leeds, United Kingdom
  • KalVista Investigative Site
    London, United Kingdom
  • KalVista Investigative Site
    Newcastle upon Tyne, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Oct 2022, 11 months.

Results were first posted in May 2026, 3 years 6 months after primary completion. A results delay was requested in Oct 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Sep 24, 2021
StartActual
Nov 18, 2021
Primary completionActual
Oct 27, 2022
CompletionActual
Oct 27, 2022
Results delay requested
Oct 5, 2023
Results first posted
May 6, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05055258
Responsible party
Sponsor
First posted
Sep 24, 2021
Start date
Nov 18, 2021
Primary completion
Oct 27, 2022
Completion
Oct 27, 2022
Results posted
May 6, 2026
Last update
May 6, 2026

Study contacts

Study Director
study director · KalVista Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Feniralstat

Start the discussion